Biktarvy vs Sunlenca
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Biktarvy | US Sunlenca |
|---|---|---|
| Generic name | bictegravir/emtricitabine/tenofovir alafenamide Unverified catalogue summary (Generic name) for Biktarvy in US; not checked against current local product information. | lenacapavir Unverified catalogue summary (Generic name) for Sunlenca in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Biktarvy in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Sunlenca in US; not checked against current local product information. |
| Treats | HIV-1 infection Unverified catalogue summary (Treats) for Biktarvy in US; not checked against current local product information. | Multidrug-resistant HIV Unverified catalogue summary (Treats) for Sunlenca in US; not checked against current local product information. |
| Category | HIV Unverified catalogue summary (Category) for Biktarvy in US; not checked against current local product information. | HIV Unverified catalogue summary (Category) for Sunlenca in US; not checked against current local product information. |
| Manufacturer | Gilead Sciences, Inc. (US labeler) Unverified catalogue summary (Manufacturer) for Biktarvy in US; not checked against current local product information. | Gilead Sciences Unverified catalogue summary (Manufacturer) for Sunlenca in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Biktarvy in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Sunlenca in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Biktarvy in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Sunlenca in US; not checked against current local product information. |
| Est. TV ad spend | $180M | — |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Biktarvy in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Sunlenca in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Biktarvy or Sunlenca better?
This directory does not compare clinical effectiveness or safety. Listing Biktarvy and Sunlenca together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Biktarvy and Sunlenca?
The table shows catalogue identification and estimated advertising information for Biktarvy and Sunlenca, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Biktarvy has the larger estimated TV advertising budget of the two.